CL2024002899A1 - Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso - Google Patents

Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso

Info

Publication number
CL2024002899A1
CL2024002899A1 CL2024002899A CL2024002899A CL2024002899A1 CL 2024002899 A1 CL2024002899 A1 CL 2024002899A1 CL 2024002899 A CL2024002899 A CL 2024002899A CL 2024002899 A CL2024002899 A CL 2024002899A CL 2024002899 A1 CL2024002899 A1 CL 2024002899A1
Authority
CL
Chile
Prior art keywords
bispecific antibodies
nrp1
binding domain
methods
antibodies
Prior art date
Application number
CL2024002899A
Other languages
English (en)
Spanish (es)
Inventor
Song Ho-Juhn
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of CL2024002899A1 publication Critical patent/CL2024002899A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2024002899A 2022-03-30 2024-09-27 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso CL2024002899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30

Publications (1)

Publication Number Publication Date
CL2024002899A1 true CL2024002899A1 (es) 2025-02-07

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002899A CL2024002899A1 (es) 2022-03-30 2024-09-27 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) * 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
CA3060190A1 (en) * 2017-04-24 2018-11-01 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Also Published As

Publication number Publication date
KR20240163751A (ko) 2024-11-19
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
JP2025511135A (ja) 2025-04-15
EP4499696A1 (en) 2025-02-05
AU2023245728A1 (en) 2024-09-26
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CN119403831A (zh) 2025-02-07
CR20240462A (es) 2024-12-11
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
CL2024002899A1 (es) Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
BR112023002895A2 (pt) Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
BR112022022800A2 (pt) Métodos para tratamento de mieloma múltiplo
PE20211860A1 (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
CO2022008314A2 (es) Anticuerpos anti–mertk y métodos de uso de los mismos
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
AR128031A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso
CO2022015049A2 (es) Péptidos de dominios knob autónomos
MX2025010708A (es) Composiciones anti-cd28
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
MX2024012474A (es) Anticuerpos anti cumulo de diferenciacion 28 (cd28) y metodos de uso de los mismos
CO2023015859A2 (es) Anticuerpos para tratar alfa-sinucleinopatías
CO2026002693A2 (es) Agentes de unión a enpp3 y cd3 y métodos de uso de estos
CO2026002111A2 (es) Anticuerpos gucy2c y usos de estos
MX2025003940A (es) Métodos para tratar cáncer con anticuerpos biespecíficos egfr x cd28 solos o en combinación con anticuerpos anti-pd-1
CO2025000447A2 (es) Moléculas de unión al antígeno anti-steap1 y sus usos
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.
PE20252587A1 (es) Anticuerpos anti-unc5c
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.